CryoPort (NASDAQ:CYRX) Hits New 12-Month High on Analyst Upgrade

Key Points

• 52-week high: CryoPort shares rose to a new 12‑month high after Guggenheim raised its price target and several analysts increased targets or issued buy ratings, leaving a consensus "Moderate Buy" with an average target around $14.44.
• Revenue beat and guidance raise: Q1 revenue came in at $47.8M (above estimates) and management lifted FY‑2026 revenue guidance to $192–$196M, signaling continued top‑line momentum driven by CGT and Life Sciences growth.
• Profitability concerns: The company missed EPS estimates and remains GAAP‑loss making with weak profitability metrics, and insiders have sold shares recently, leaving valuation dependent on sustained revenue/CGT growth.

CryoPort, Inc. (NASDAQ:CYRX - Get Free Report) reached a new 52-week high on Wednesday after Guggenheim raised their price target on the stock from $11.00 to $12.00. Guggenheim currently has a buy rating on the stock. CryoPort traded as high as $12.65 and last traded at $12.19, with a volume of 2210037 shares changing hands. The stock had previously closed at $10.21.

A number of other equities analysts also recently commented on the company. Craig Hallum assumed coverage on CryoPort in a research report on Monday, March 30th. They set a "buy" rating and a $15.00 price objective for the company. BTIG Research boosted their price objective on CryoPort from $15.00 to $17.00 and gave the stock a "buy" rating in a research report on Tuesday. Wall Street Zen downgraded CryoPort from a "hold" rating to a "sell" rating in a research report on Sunday. Weiss Ratings reissued a "sell (d+)" rating on shares of CryoPort in a research report on Friday, March 27th. Finally, Needham & Company LLC boosted their price objective on CryoPort from $13.00 to $15.00 and gave the stock a "buy" rating in a research report on Tuesday. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $14.44.

Insider Activity at CryoPort

In related news, CEO Jerrell Shelton sold 7,918 shares of the company's stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $8.00, for a total value of $63,344.00. Following the completion of the transaction, the chief executive officer directly owned 1,054,501 shares of the company's stock, valued at $8,436,008. This represents a 0.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Mark W. Sawicki sold 3,235 shares of the company's stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $8.00, for a total value of $25,880.00. Following the completion of the transaction, the insider directly owned 103,697 shares of the company's stock, valued at $829,576. This trade represents a 3.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 59,939 shares of company stock valued at $471,183 over the last three months. 10.10% of the stock is owned by corporate insiders.

Key CryoPort News

Here are the key news stories impacting CryoPort this week:

• Positive Sentiment: Q1 revenue beat and healthy growth — Revenue was $47.8M (vs. ~$44.9M est.), up 16% year‑over‑year; Commercial cell & gene therapy (CGT) revenue grew 26% to $9.1M and Life Sciences segments also grew. Press Release
• Positive Sentiment: Company raised FY‑2026 revenue guidance to $192M–$196M, slightly above consensus — management is signaling continued top‑line momentum. Press Release
• Positive Sentiment: Analyst upgrades / price‑target increases — BTIG raised its target to $17 (buy) and Needham raised its target to $15 (buy), providing fresh buy‑side support. The Fly (BTIG) TickerReport (Needham)
• Neutral Sentiment: Investor materials and transcripts available — full Q1 slide deck and earnings‑call transcript were published for deeper diligence. Earnings Call Transcript Slide Deck
• Neutral Sentiment: Market action reflects the news flow — the stock is trading higher on elevated volume as the market re‑prices growth vs. near‑term profitability concerns.
• Negative Sentiment: EPS missed estimates — reported an EPS loss (reported -$0.25 vs. -$0.20 consensus per MarketBeat / other outlets), underscoring ongoing GAAP losses. MarketBeat Earnings
• Negative Sentiment: Profitability metrics remain weak — negative return on equity and continued GAAP losses mean valuation relies on sustained revenue/CGT momentum. Zacks

Hedge Funds Weigh In On CryoPort

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Penbrook Management LLC boosted its holdings in CryoPort by 251.6% in the first quarter. Penbrook Management LLC now owns 185,775 shares of the company's stock valued at $1,538,000 after purchasing an additional 132,940 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in CryoPort by 0.6% in the first quarter. Assenagon Asset Management S.A. now owns 1,495,683 shares of the company's stock valued at $12,384,000 after purchasing an additional 8,280 shares in the last quarter. Corient Private Wealth LLC acquired a new position in CryoPort in the fourth quarter valued at approximately $113,000. Invesco Ltd. boosted its holdings in CryoPort by 19.3% in the fourth quarter. Invesco Ltd. now owns 96,541 shares of the company's stock valued at $927,000 after purchasing an additional 15,607 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in CryoPort in the fourth quarter valued at approximately $424,000. 92.90% of the stock is owned by institutional investors and hedge funds.

CryoPort Price Performance

The stock has a 50 day simple moving average of $8.99 and a two-hundred day simple moving average of $9.34. The company has a market cap of $611.94 million, a PE ratio of 9.03 and a beta of 1.75.

CryoPort (NASDAQ:CYRX - Get Free Report) last issued its quarterly earnings data on Monday, May 4th. The company reported ($0.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.03). CryoPort had a net margin of 41.57% and a negative return on equity of 7.84%. The firm had revenue of $47.80 million during the quarter, compared to analysts' expectations of $44.86 million. As a group, equities analysts anticipate that CryoPort, Inc. will post -0.73 EPS for the current fiscal year.

CryoPort Company Profile

CryoPort, Inc NASDAQ: CYRX is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort's product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.